Trabeculectomy training in need of improvement

Article

Trabeculectomy is in danger of becoming a technique performed only by sub-specialists with glaucoma fellowship training unless it becomes a mandatory feature in training programmes.

Trabeculectomy is in danger of becoming a technique performed only by sub-specialists with glaucoma fellowship training unless it becomes a mandatory feature in training programmes, according to a report published online ahead of print in Eye.

Graham Lee and colleagues from The University of Queensland, The Royal Brisbane Hospital and the Brisbane North Eye Centre, Australia, conducted a retrospective, consecutive case review to analyse the rates and outcomes of trabeculectomies performed by ophthalmology trainees and consultants.

During the study period, 290 primary trabeculectomies were performed. Trainees performed 33% of procedures, representing a rate of 1.6 procedures per year per trainee. Rates of postoperative complications were similar between the trainees and the consultants, however, the percentage of patients achieving an IOP of 15 mmHg in the absence of medications at their last follow-up was low, at just 30%.

The researchers believe that improvements are required in the ophthalmic training programme in order that the appropriate skills are learned and maintained. They warn that, if this does not happen, trabeculectomies could become a procedure performed only by sub-specialist groups.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.